Neuropeptides, including mammalian bombesin-like peptides gastrin and cholecystokinin, are a structurally diverse group of molecular messengers that function in a rich network of intercellular of intercellular communication. These signaling peptides have been identified in our laboratory as potent cellular growth factors. Neuropeptides and their receptors are a major driving force behind one of the most clinically aggressive cancers, small cell lung cancer (SCLC). Our central hypothesis is that the surface receptors and the intracellular signaling pathways that mediate the proliferative and migratory responses induced by neuropeptides are potential targets for novel therapeutic interventions. Given the pivotal role of the protein kinase C (PKC) family in neuropeptide signal transduction, the studies proposed under specific aim 1 will focus on the novel PKC/PKD phosphorylation cascade in SCLC cells. Antagonists capable of blocking the biological effects of structurally unrelated neuropeptides (e.g., broad-spectrum neuropeptide antagonists) either at receptor or post-receptor levels could provide a novel approach to the treatment of SCLC and other human cancers in which multiple neuropeptides are involved as growth factors. Substance P (SP) analogues have been found in our laboratory to inhibit signal transduction and cell proliferation induced by multiple neuropeptides. These broad-spectrum neuropeptide antagonists also inhibit the proliferation of SCLC cell lines in culture, the growth of SCLC xenografts in nude mice and have entered a phase I clinical trial. As broad-spectrum neuropeptide antagonists could provide a novel approach to the treatment of SCLC and solid cancers, it is of critical importance to understand their mechanism of action. The studies proposed under specific aims 2-4 will characterize the molecular mechanism(s) by which SP analogues inhibit the binding and action of different neuropeptides.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090388-02
Application #
6594425
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-05-31
Project End
2002-12-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Lee, Jay M; Lee, Mi-Heon; Garon, Edward et al. (2017) Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clin Cancer Res 23:4556-4568
Kawakita, Daisuke; Lee, Yuan-Chin Amy; Turati, Federica et al. (2017) Dietary fiber intake and head and neck cancer risk: A pooled analysis in the International Head and Neck Cancer Epidemiology consortium. Int J Cancer 141:1811-1821
Boffetta, Paolo; Hayes, Richard B; Sartori, Samantha et al. (2016) Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev 25:344-8
Miles, Fayth L; Chang, Shen-Chih; Morgenstern, Hal et al. (2016) Association of sugary beverages with survival among patients with cancers of the upper aerodigestive tract. Cancer Causes Control 27:1293-1300
Wyss, Annah B; Hashibe, Mia; Lee, Yuan-Chin Amy et al. (2016) Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis of US Studies in the INHANCE Consortium. Am J Epidemiol 184:703-716
Leoncini, Emanuele; Edefonti, Valeria; Hashibe, Mia et al. (2016) Carotenoid intake and head and neck cancer: a pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Eur J Epidemiol 31:369-83
Hashim, D; Sartori, S; Brennan, P et al. (2016) The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. Ann Oncol 27:1619-25
Myneni, Ajay A; Chang, Shen-Chih; Niu, Rungui et al. (2016) Raw Garlic Consumption and Lung Cancer in a Chinese Population. Cancer Epidemiol Biomarkers Prev 25:624-33
Alavi, Mohammed; Mah, Vei; Maresh, Erin L et al. (2015) High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer 15:655
Reckamp, Karen L; Koczywas, Marianna; Cristea, Mihaela C et al. (2015) Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer 121:3298-306

Showing the most recent 10 out of 201 publications